hasMolecularTarget

P37016
predicate

Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).

All labels observed (28)

Label Occurrences
targetOfDrug 48
hasMolecularTarget canonical 28
therapeuticTargetOf 15

Description generation (PDg)

The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.

Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning.  
# Instructions
Focus on describing the relationship, not the entities themselves. 
# Response Format
Begin the description with \' Indicates...\'
Input
Predicate: hasMolecularTarget
Generated description
Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).

Sample triples (180)

Subject Object
MAGL enzyme
surface form: MAGL
analgesic agents via predicate surface "drugTargetFor"
MAGL enzyme
surface form: MAGL
anti-inflammatory agents via predicate surface "drugTargetFor"
MAGL enzyme
surface form: MAGL
neuroprotective agents via predicate surface "drugTargetFor"
MAGL enzyme
surface form: MAGL
anticancer agents via predicate surface "drugTargetFor"
pirtobrutinib tyrosine kinase via predicate surface "hasMolecularTargetClass"
EGFR gefitinib via predicate surface "targetOfDrug" NERFINISHED
EGFR erlotinib via predicate surface "targetOfDrug" NERFINISHED
EGFR afatinib via predicate surface "targetOfDrug" NERFINISHED
EGFR osimertinib via predicate surface "targetOfDrug" NERFINISHED
EGFR dacomitinib via predicate surface "targetOfDrug" NERFINISHED
EGFR cetuximab via predicate surface "targetOfDrug"
EGFR panitumumab via predicate surface "targetOfDrug" NERFINISHED
EGFR necitumumab via predicate surface "targetOfDrug" NERFINISHED
fam-trastuzumab deruxtecan ERBB2 NERFINISHED
MS4A1 gene
surface form: MS4A1
rituximab via predicate surface "targetOfDrug" NERFINISHED
MS4A1 gene
surface form: MS4A1
ofatumumab via predicate surface "targetOfDrug" NERFINISHED
MS4A1 gene
surface form: MS4A1
obinutuzumab via predicate surface "targetOfDrug" NERFINISHED
MS4A1 gene
surface form: MS4A1
ocrelizumab via predicate surface "targetOfDrug"
MS4A1 gene
surface form: MS4A1
ublituximab via predicate surface "targetOfDrug" NERFINISHED
BAFF belimumab via predicate surface "targetOfDrug"
BAFF tabalumab via predicate surface "targetOfDrug" NERFINISHED
BAFF blisibimod via predicate surface "targetOfDrug" NERFINISHED
BAFF atacicept via predicate surface "targetOfDrug" NERFINISHED
interleukin-4 dupilumab via predicate surface "isTargetOfDrug" NERFINISHED
interleukin-4 pitrakinra via predicate surface "isTargetOfDrug" NERFINISHED
interleukin-4 pascolizumab via predicate surface "isTargetOfDrug" NERFINISHED
CLinical Evaluation Of Pertuzumab And TRAstuzumab
surface form: CLEOPATRA trial
HER2 via predicate surface "targetMolecule" NERFINISHED
CLinical Evaluation Of Pertuzumab And TRAstuzumab
surface form: CLEOPATRA trial
HER2 dimerization domain via predicate surface "pertuzumabTarget"
CLinical Evaluation Of Pertuzumab And TRAstuzumab
surface form: CLEOPATRA trial
HER2 extracellular domain via predicate surface "trastuzumabTarget" NERFINISHED
Corynebacterium diphtheriae elongation factor 2 via predicate surface "targetMolecule"